University of Virginia: Breast Neoplasms trials

The registry lists 16 Breast Neoplasms studies with University of Virginia as lead sponsor. 5 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 5Phase 2 5Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive DesignNot yet recruitingNCT07721064Not applicable
• A Pre-post Pilot of a Smartphone InterventionNot yet recruitingNCT07665346Not applicable
• HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)RecruitingNCT07441889Phase 1/2
• Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingNCT06507618Phase 3
• Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerRecruitingNCT05288777Phase 2/3
• Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer SurvivorsCompletedNCT07160439Not applicableResults posted
• Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive DesignCompletedNCT04583891Not applicableResults posted
• Her2-BATS and Pembrolizumab in Metastatic Breast CancerActive, not recruitingNCT03272334Phase 1/2Results posted
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast CancerCompletedNCT00304096Phase 1Results posted
• The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic ChemotherapiesCompletedNCT05786014Not applicable
• COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast CancerWithdrawnNCT04038489Phase 2
• BATs in Patients With Breast Cancer and Leptomeningeal MetastasesTerminatedNCT03661424Phase 1
• Immune Effects in Patients Treated With Whole Breast IrradiationStatus unknownNCT03567044Not applicable
• Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerWithdrawnNCT03473691Early Phase 1
• A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant TherapyCompletedNCT03473639Phase 1
• IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery:CompletedNCT01204242Phase 2